TG Therapeutics Reports Monday with Buyout Whispers Louder Than Its Profit Trajectory

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

TG Therapeutics has not consistently reported at a specific time, with recent reports filed during various parts of the trading day, making Day 0 moves reflect a mix of anticipation and immediate reaction depending on timing.

Historical price behavior around earnings shows significant volatility with an average absolute Day 0 move of 11.24% and Day 0 range of 13.34%. The direction has been mixed but tilted negative in recent quarters: the August 2026 report triggered an -11.26% decline, while May 2026 saw a strong +16.26% rally despite the earnings miss. The February 2026 report produced a modest +4.18% gain, but November 2025 fell -3.13%, and August 2025 dropped sharply by -17.99%.

Day +1 follow-through has been more muted, averaging 3.66% with a 7.00% range, suggesting most of the price discovery occurs in the immediate reaction. Notably, the stock has shown a tendency for sharp reversals: the May 2026 miss was followed by a +16.26% rally, while the massive September 2025 beat (+912.50%) was followed by a Day 0 decline. Investors should prepare for a potential double-digit percentage move in either direction, with recent history suggesting downside risk on disappointing results but also capacity for strong rallies if the company can demonstrate improving fundamentals.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 12.99% (approximately $7.95) for the November expiration, which is slightly above the historical average Day 0 move of 11.24% but below the average Day 0 range of 13.34%. This suggests options traders are anticipating volatility consistent with recent history, though not at the extreme levels seen in some prior quarters like August 2025's -17.99% plunge or May 2026's +16.26% surge.

Part 3: What Analysts Are Saying

Wall Street analysts maintain a Buy consensus on TG Therapeutics with an average rating of 4.22 on the five-point scale. The current analyst cohort includes 6 Strong Buy ratings, 2 Hold ratings, and 1 Moderate Sell rating, for a total of 9 analysts covering the stock. The average price target stands at $64.38, with a high estimate of $86.00 and a low of $21.00—a remarkably wide range that reflects divergent views on the company's prospects.

From the current price of $61.18, the consensus target implies upside of approximately 5.2%, suggesting analysts see modest appreciation potential in the near term. However, the high target of $86.00 represents 40.6% upside, indicating some analysts remain highly bullish on the company's long-term trajectory, while the low target of $21.00 implies -65.7% downside risk if the bearish case materializes.

Sentiment has improved over the past month, with the average recommendation strengthening from 4.00 to 4.22. The number of Hold ratings increased from 1 to 2, while Strong Sells decreased from 1 to 0, suggesting some analysts have upgraded their stance despite the recent earnings disappointments. This improving sentiment may reflect optimism about BRIUMVI's commercial trajectory or expectations that the company is approaching an inflection point in profitability, though the persistence of a Moderate Sell rating indicates not all analysts are convinced the turnaround story will materialize.

Part 4: Technical Picture

The Barchart Technical Opinion rates TGTX as a Buy at 88%, showing dramatic strengthening from 40% last week and 64% last month. This sharp improvement in the technical signal reflects powerful momentum as the stock has surged to new 52-week highs heading into the earnings release.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum is positive but not overwhelming, indicating some consolidation or profit-taking may be occurring at these elevated levels
• Medium-term (100% Buy): Strong buy signal across all medium-term indicators reflects robust momentum in the intermediate timeframe, supporting the recent breakout to new highs
• Long-term (100% Buy): Unanimous buy signal in the longer-term trend confirms the stock has established a sustained uptrend, with the 200-day moving average providing strong support

Trend Characteristics: The Strong strength combined with Strongest direction indicates TGTX is in a powerful uptrend with exceptional momentum heading into earnings, creating both opportunity and risk depending on whether results can justify the recent rally.

The stock is trading above all major moving averages, with the current price of $61.18 well above the 200-day moving average at $43.81 (+39.6%), the 100-day at $54.01 (+13.3%), and the 50-day at $55.33 (+10.6%). Shorter-term averages show similar strength: above the 20-day at $54.90, the 10-day at $55.63, and the 5-day at $57.58. The stock recently hit a new 52-week high of $61.76, indicating it's trading at the upper end of its range with no overhead resistance.

This technical setup is a double-edged sword heading into earnings. On one hand, the strong uptrend and positioning above all moving averages suggest institutional support and positive momentum that could amplify gains on a positive surprise. On the other hand, the stock's extended position at 52-week highs leaves it vulnerable to sharp profit-taking if results disappoint, particularly given the pattern of recent earnings misses. The 50-day moving average at $55.33 represents the first meaningful support level (-9.6% from current levels), while the 200-day at $43.81 would mark a more significant retracement zone. Investors should be prepared for heightened volatility, as the combination of strong technical momentum and elevated expectations creates conditions for an outsized move in either direction.